Global Atrophic Gastritis Treatment Market Growth (Status and Outlook) 2023-2029

Global Atrophic Gastritis Treatment Market Growth (Status and Outlook) 2023-2029

Atopic gastritis is chronic inflammation of gastric mucosa, and it is a histopathological condition associated with gastric glandular cell and replacement by fibrous tissue, intestinal type epithelium, and pyloric type glands. It mainly associated H. Pylori bacterial infection, and autoimmunity directed against gastric glandular cell. Symptoms include stomach pain, loss of appetite, nausea, unexpected weight loss, iron deficiency anemia. There is a high chance for the development of pernicious anemia in autoimmune atrophic gastritis Individual due to the loss of anti-intrinsic antibodies and parietal cell mass. Atrophic gastritis associated with H. Pylori are at high risk of developing gastric carcinoma and is frequently asymptomatic. Individuals associated with chronic atrophic gastritis develop hypergastrinemia and low gastric acid output which may lead to carcinoid tumors and enterochromaffin-like cell hyperplasia. Atrophic gastritis develops at childhood and if, it is left untreated atrophic gastritis progress throughout the lifespan. Treatment mainly includes antibiotics for eliminating H. Pylori bacteria. Symptomatic treatment includes vitamin B-12 injections. Proton pump inhibitors used to control the acidity of the stomach. Autoimmune atrophic gastritis associated with gastric polyps, pernicious anemia, and adenocarcinoma. Atrophic gastritis diagnosed by low levels of B-12, low levels of pepsinogen, high levels of gastrin and intrinsic factors.

LPI (LP Information)' newest research report, the “Atrophic Gastritis Treatment Industry Forecast” looks at past sales and reviews total world Atrophic Gastritis Treatment sales in 2022, providing a comprehensive analysis by region and market sector of projected Atrophic Gastritis Treatment sales for 2023 through 2029. With Atrophic Gastritis Treatment sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Atrophic Gastritis Treatment industry.

This Insight Report provides a comprehensive analysis of the global Atrophic Gastritis Treatment landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Atrophic Gastritis Treatment portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Atrophic Gastritis Treatment market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Atrophic Gastritis Treatment and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Atrophic Gastritis Treatment.

The global Atrophic Gastritis Treatment market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

Atrophic gastritis is associated with loss of gastric gland and is a progressive condition with the replacement of metaplasia. It is asymptomatic and associated with large complications like gastric carcinoma, hyperplasia, hypergastrinemia, increased risk of heart attack in elderly. The frequency of atrophic gastritis is unknown due to it is mostly asymptomatic. Atrophic gastritis is extremely common and is highly prevalent in different parts of the globe. In atrophic gastritis, eradication of H. Pylori is highly complicated, and it requires follow-up for several years. Eradication of H. Pylori reduces the risk of developing cancers in late stages. Mortality and morbidity associated with atrophic gastritis are depended on underlying complications of diseases. Atrophic gastritis requires a continuous management because recurrence of illness is high. All these factors act as a driver in the robust growth of the atrophic gastritis treatment market.

This report presents a comprehensive overview, market shares, and growth opportunities of Atrophic Gastritis Treatment market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Coating Agents
Antibiotics
Vitamin B-12

Segmentation by application
Hospital Pharmacies
Retail Pharmacies
Drug Stores
Online Pharmacies

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Takeda Pharmaceutical Company Limited
PERNIX Therapeutics
Perrigo Pharmaceutical
Teva Pharmaceutical

Please note: The report will take approximately 2 business days to prepare and deliver.